IP Library Granted Patent US 7,461,658
Granted Patent B2
US 7,461,658 · App. 11/973,056 · Granted Dec 9, 2008

Methods for treating eye conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,461,658
App. No.
11/973,056
Granted
Dec 9, 2008
Kind
B2
Abstract

Architectures and techniques for treating conditions of the eye, such as presbyopia, utilize sources of treatment energy, such as electromagnetic energy emitting devices, to implement non-corneal manipulations. According to these devices and methods, the sources of treatment energy are activated to direct energy onto parts of the eye, such as the conjunctiva and sclera, to treat presbyopia. The treatments can affect at least one property of the eye and enhance an accommodation of the eye.

Claims (42)

1. A method for treating an eye in need of one or more of a physiological and a vision correction, comprising directing treatment energy through a conjunctiva and onto a sclera, an intersection of the treatment energy and the conjunctiva having a first shape and a first area, and an intersection of the treatment energy and the sclera having a first reference shape and a first reference area, wherein the directing is characterized by one or more of the following non-equivalent and non-interchangeable features: (a) a maximum dimension of the first shape is greater than a maximum dimension of the first reference shape, (b) the first area is greater than the first reference area, and (c) a maximum concentration or intensity of treatment energy in the first area is less than a maximum concentration or intensity of treatment energy in the first reference area.

2. The method as set forth in claim 1 , wherein a characteristic or measurable parameter of the treatment energy tapers within the sclera from about 1 to about 100 percent with each 1 percent drop in depth within the sclera.

3. The method as set forth in claim 2 , wherein the characteristic or measurable parameter is a dimension of the treatment energy.

4. The method as set forth in claim 3 , wherein the dimension is a diameter of the treatment energy.

5. The method as set forth in claim 4 , wherein a profile of the treatment energy has one or more of a conical and a “V” shape.

6. The method as set forth in claim 1 , wherein a characteristic or measurable parameter of the treatment energy drops by about 1 to about 20 percent for each 1 percent drop in depth within the sclera.

7. The method as set forth in claim 6 , wherein the characteristic or measurable parameter is a dimension of the treatment energy.

8. The method as set forth in claim 7 , wherein the dimension is a diameter of the treatment energy.

9. The method as set forth in claim 8 , wherein a profile of the treatment energy has one or more of a conical and a “V” shape.

10. The method as set forth in claim 1 , wherein a maximum dimension of the first shape is greater than a maximum dimension of the first reference shape.

11. The method as set forth in claim 1 , wherein the first area is greater than the first reference area.

12. The method as set forth in claim 1 , wherein a maximum concentration or intensity of treatment energy in the first area is less than a maximum concentration or intensity of treatment energy in the first reference area.

13. The method as set forth in claim 1 , wherein the treatment energy has a focal point, which is on or in the sclera.

14. The method as set forth in claim 1 , wherein the treatment energy is focused on or into the sclera more so than on the conjunctiva.

15. The method as set forth in claim 1 , wherein the treatment energy is focused on or into the sclera to an extent, which is greater than an extent to which the treatment energy is focused on or into the conjunctiva.

16. The method as set forth in claim 1 , wherein treatment energy is focused on or inside the sclera rather than on the conjunctiva.

17. The method as set forth in claim 1 , wherein portions of the conjunctiva penetrated by the treatment energy are not substantially affected by the treatment energy.

18. The method as set forth in claim 1 , wherein portions of the conjunctiva penetrated by the treatment energy are not substantially ablated by the treatment energy.

19. The method as set forth in claim 1 , wherein portions of the conjunctiva penetrated by the treatment energy are affected to a lesser extent than the extent to which the sclera is affected by the treatment energy.

20. The method as set forth in claim 1 , wherein the treatment energy is directed non-invasively through the conjunctiva.

21. The method as set forth in claim 1 , wherein the treatment energy comprises a beam of electromagnetic energy.

22. The method as set forth in claim 1 , wherein the treatment energy is a beam of electromagnetic energy.

23. The method as set forth in claim 1 , wherein the treatment energy is a beam of laser light.

24. The method as set forth in claim 1 , wherein the treatment energy is directed through the conjunctiva in a manner so that the intersection of the treatment energy and the conjunctiva has the shape of a spot.

25. The method as set forth in claim 1 , wherein the treatment energy forms a pattern in the sclera that is smaller than a pattern formed in the conjunctiva by the treatment energy.

26. The method as set forth in claim 1 , wherein the sclera, but not the conjunctiva, is ablated.

27. The method as set forth in claim 26 , wherein a portion of the conjunctiva is rotated or shifted, relative to the sclera, from a first configuration to a second configuration, before the sclera is ablated.

28. The method as set forth in claim 27 , wherein the ablating of the sclera is followed by rotating or shifting at least part of the portion in a direction back to the first configuration.

29. The method as set forth in claim 1 , wherein:

the treatment energy comprises a beam of treatment energy;

the beam is directed through the conjunctiva in a manner so that the intersection of the beam and the conjunctiva has the shape of a spot; and

the beam forms one or more of a plurality of adjacent radial lines and a plurality of substantially parallel lines.

30. The method as set forth in claim 1 , wherein the treatment energy comprises a first beam of treatment energy and the method further comprises directing a second beam of treatment energy through the conjunctiva and onto a sclera, wherein an intersection of the second beam and the conjunctiva has a second shape and a second area, an intersection of the second beam and the sclera having a second reference shape and a second reference area, and wherein the directing is characterized by one or more of the following non-equivalent and non-interchangeable features: (a) a maximum dimension of the second shape is greater than a maximum dimension of the second reference shape, (b) the second area is greater than the second reference area, and (c) a maximum concentration or intensity of treatment energy in the second area is less than a maximum concentration or intensity of treatment energy in the second reference area.

31. The method as set forth in claim 30 , wherein the method further comprises directing a third beam of treatment energy through the conjunctiva and onto a sclera, wherein an intersection of the third beam and the conjunctiva has a third shape and a third area, an intersection of the third beam and the sclera having a third reference shape and a third reference area, and wherein the directing is characterized by one or more of the following non-equivalent and non-interchangeable features: (a) a maximum dimension of the third shape is greater than a maximum dimension of the third reference shape, (b) the third area is greater than the third reference area, and (c) a maximum concentration or intensity of treatment energy in the third area is less than a maximum concentration or intensity of treatment energy in the third reference area.

32. The method as set forth in claim 31 , wherein:

the directing of each of the second beam and the third beam comprises rotating or shifting a portion of the conjunctiva, relative to the sclera, from a first configuration to a second configuration; and

the directing of each of the second beam and the third beam is followed by rotating or shifting at least part of the portion in a direction back to the first configuration.

33. The method as set forth in claim 32 , wherein:

the second and third beams are directed through the conjunctiva in manners so that the intersection of each and the conjunctiva has the shape of a spot;

the beam forms one or more of a plurality of adjacent radial lines and a plurality of substantially parallel lines; and

each of the second beam and the third beam forms one or more of a plurality of adjacent radial lines and a plurality of substantially parallel lines.

34. The method as set forth in claim 1 , wherein the treatment energy is directed invasively on or into the sclera.

Assignments (10)
SECURITY INTEREST Recorded Oct 30, 2019
From: BIOLASE, INC.
To: PACIFIC MERCANTILE BANK
Reel/Frame 050879/0223 →
SECURITY INTEREST Recorded Nov 16, 2018
From: BIOLASE, INC.
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 047588/0192 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2018
From: WESTERN ALLIANCE BANK
To: BIOLASE, INC.
Reel/Frame 048101/0027 →
SECURITY INTEREST Recorded Mar 7, 2018
From: BIOLASE, INC.
To: WESTERN ALLIANCE BANK
Reel/Frame 045514/0540 →
CHANGE OF NAME Recorded Nov 20, 2012
From: BIOLASE TECHNOLOGY, INC.
To: BIOLASE, INC.
Reel/Frame 029328/0096 →
RELEASE OF SECURITY INTEREST Recorded May 9, 2012
From: HENRY SCHEIN, INC.
To: BIOLASE TECHNOLOGY, INC.; BL ACQUISTION CORP.; BL ACQUISITION II INC.
Reel/Frame 028184/0218 →
SECURITY AGREEMENT PAYOFF Recorded May 16, 2011
From: MIDCAP FINANCIAL, LLC, AGENT AND AS LENDER
To: BIOLASE TECHNOLOGY, INC.
Reel/Frame 026285/0666 →
SECURITY AGREEMENT Recorded Sep 30, 2010
From: BIOLASE TECHNOLOGY, INC.; BL ACQUISITION CORP.; BL ACQUISITION II INC.
To: HENRY SCHEIN, INC.
Reel/Frame 025066/0488 →
SECURITY AGREEMENT Recorded Aug 28, 2010
From: BIOLASE TECHNOLOGY, INC.
To: MIDCAP FINANCIAL, LLC, AS AGENT AND AS A LENDER
Reel/Frame 024900/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2007
From: JONES, JEFFREY W.; VAN VALEN, MARCIA ANGELA
To: BIOLASE TECHNOLOGY, INC.
Reel/Frame 019981/0273 →